Venture-backed Zymeworks files for Canadian and U.S. IPO
Vancouver-based biotherapeutics company Zymeworks Inc has filed with Canadian and U.S. regulatory authorities for an initial public offering of its common shares. The IPO, which will give the company a listing on the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbol “ZYME”, has not been officially priced; however, the U.S. Securities and Exchange Commission notes a proposed offering size of as much as $100 million (US$75 million). Last year, Zymeworks closed one of Canada's largest venture capital rounds, raising about $87 million (US$61.5 million). It was led by BDC Capital and Lumira Capital and joined by multiple other investors.
3 April 2017•3 mins read
